• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

    9/16/25 8:00:39 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email

    LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced its first HYPE Asset Use Service ("HAUS") agreement with proprietary trading firm Credo Cayman ("Credo").

    Through this first-of-its-kind on-chain service, Hyperion DeFi provides the use of 100,000 staked HYPE to Credo, enabling the firm to substantially reduce transaction fees when trading on Hyperliquid. The resulting net fee savings will be shared between the two companies, creating a new revenue stream for both.

    "Hyperion DeFi's launch of HAUS Credo further demonstrates the Company's ability to access novel revenue-generating opportunities via the unique decentralized finance primitives only available on Hyperliquid," said Hyunsu Jung, Interim Chief Executive Officer of Hyperion DeFi. "This deal is a key step in our broader, long-term vision to establish and scale revenues from onboarding more financial activity onto Hyperliquid."

    Credo's team is comprised of experienced traders and technologists with decades of combined expertise in both traditional and digital asset markets. They currently provide liquidity across a wide range of asset classes as part of managing a proprietary trading book. The team has expanded from accessing derivatives on centralized venues, such as Coinbase and Binance, to Hyperliquid, which offers significantly lower fees and comparable trade settlement speeds.

    About the Hyperliquid Platform and the HYPE Token

    Hyperliquid is a layer one blockchain (L1) optimized from the ground up for high frequency, transparent trading. The blockchain includes fully on-chain perpetual futures and spot order books, with every order, cancel, trade, and liquidation occurring within 70 millisecond block times. It also hosts the HyperEVM, a general-purpose smart contract platform that, like Ethereum, supports permissionless decentralized financial applications.

    HYPE is the native token of Hyperliquid. Staked HYPE in particular provides utility for users via reduced trading fees and increased referral bonuses. Circulating HYPE is autonomously purchased and sequestered by the blockchain itself with the trading fees generated on the network's order books. As of September 2025, more than 30 million HYPE has been sequestered by this mechanism, and the token has become the 16th-largest cryptocurrency by market capitalization.

    About Hyperion DeFi, Inc.

    Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. The Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.

    Hyperion DeFi is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.

    For more information, please visit Hyperiondefi.com.

    About Credo

    Credo is a proprietary trading firm engaged in multiple trading strategies across traditional and digital asset markets. Credo is based in the Cayman Islands.

    For more information, please visit https://www.credo-v.com/.

    Forward Looking Statements

    Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, and the growth and revenue potential of the Hyperliquid ecosystem and the growth prospects of the Company. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission, including in particular, the risks of our cryptocurrency strategy as detailed in our Current Report on Form 8-K filed on June 27, 2025.

    Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Hyperion DeFi does not undertake any obligation to update any forward-looking statements.

    Hyperion DeFi, Inc. Investor Contact:

    Jason Assad

    Hyperion DeFi, Inc.

    [email protected]

    (678) 570-6791



    Primary Logo

    Get the next $HYPD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYPD
    SEC Filings

    View All

    SEC Form 424B5 filed by Hyperion DeFi Inc.

    424B5 - HYPERION DEFI, INC. (0001682639) (Filer)

    9/24/25 7:21:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    9/24/25 7:14:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    9/8/25 4:12:49 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Walters Happy David was granted 50,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:08:07 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Walters Happy David

    3 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:07:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Jung Hyunsu was granted 1,000,000 shares, increasing direct ownership by 200% to 1,500,000 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    8/20/25 4:49:06 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

    LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced its first HYPE Asset Use Service ("HAUS") agreement with proprietary trading firm Credo Cayman ("Credo"). Through this first-of-its-kind on-chain service, Hyperion DeFi provides the use of 100,000 staked HYPE to Credo, enabling the firm to substantially reduce transaction fees when trading on Hyperliquid. The resulting net fee savings will be shared between the two companies, creating a new revenue stream for both. "Hyperion DeFi's l

    9/16/25 8:00:39 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Treasury Revolution Accelerates as $113 Billion Bitcoin Holdings Spark 150% Stock Surges

    USA News Group News Commentary Issued on behalf of CEA Industries, Inc. VANCOUVER, BC, Sept. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Earlier this summer, Animoca Brands released a report stating corporate treasury companies surge an average of 150% within 24 hours of announcing crypto adoption strategies[1] as digital asset treasuries amass $113 billion in Bitcoin stockpiles through September 2025, according to Coingecko data[2]. The explosive momentum reflects a fundamental shift from traditional cash reserves to strategic cryptocurrency accumulation, with U.S. Bank resuming Bitcoin custody services for institutional clients following greater regulatory clarity and institu

    9/12/25 9:00:00 AM ET
    $BNC
    $DFDV
    $HYPD
    Industrial Machinery/Components
    Industrials
    Finance: Consumer Services
    Finance

    Hyperion DeFi Strengthens Leadership Team With Key Appointments to Accelerate DeFi Strategy

    Hyunsu Jung Named Interim CEO; CFO Appointment Confirmed, Underscoring Focus on Decentralized Finance Board Expansion and Continued Strategic Advisory Designed to Drive Growth and Execution LAGUNA HILLS, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), today announced a series of strategic leadership updates designed to strengthen governance and accelerate its decentralized finance ("DeFi") strategy. Mr. Michael Rowe has notified the Company of his intent to resign from his position as Chief Executive Officer of the Company. Pending the effectiveness of Mr. Rowe's resignation, Hyunsu Jung, who is currently the Company's Chi

    9/9/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care